Haemodialysis (HD) is a life-saving therapy for individuals with kidney failure. Post-filter haemodiafiltration (HDF) and high-flux HD are among the most widely used treatment modalities of kidney failure. To date, 10 randomized controlled trials (RCTs) have compared all-cause and cardiovascular (CV) mortality between pre- or post-filter HDF and low- or high-flux HD in adults undergoing maintenance dialysis for at least 1 year [1–10].
On the fragility of outcome measures of two individual patient data analyses from randomized controlled trials on online haemodiafiltration / Basile, C., Mantovani, A., Battaglia, Y.. - In: NEPHROLOGY DIALYSIS TRANSPLANTATION. - ISSN 0931-0509. - 2025, 40:9(2025), pp. 1806-1808. [10.1093/ndt/gfaf085]
On the fragility of outcome measures of two individual patient data analyses from randomized controlled trials on online haemodiafiltration
Battaglia, Yuri
2025-01-01
Abstract
Haemodialysis (HD) is a life-saving therapy for individuals with kidney failure. Post-filter haemodiafiltration (HDF) and high-flux HD are among the most widely used treatment modalities of kidney failure. To date, 10 randomized controlled trials (RCTs) have compared all-cause and cardiovascular (CV) mortality between pre- or post-filter HDF and low- or high-flux HD in adults undergoing maintenance dialysis for at least 1 year [1–10].| File | Dimensione | Formato | |
|---|---|---|---|
|
gfaf085.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
339.78 kB
Formato
Adobe PDF
|
339.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
